• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cytek Biosciences Set to Join S&P SmallCap 600

    4/25/23 5:54:00 PM ET
    $ABT
    $CSII
    $CTKB
    $SPGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ABT alert in real time by email

    NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    May 1, 2023

    S&P SmallCap 600

    Addition

    Cytek Biosciences

    CTKB

    Health Care



    S&P SmallCap 600

    Deletion

    Cardiovascular Systems

    CSII

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/cytek-biosciences-set-to-join-sp-smallcap-600-301807529.html

    SOURCE S&P Dow Jones Indices

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $CSII
    $CTKB
    $SPGI

    CompanyDatePrice TargetRatingAnalyst
    S&P Global Inc.
    $SPGI
    2/17/2026$575.00Buy
    BofA Securities
    Cytek Biosciences Inc.
    $CTKB
    12/2/2025$6.00Equal-Weight
    Morgan Stanley
    Abbott Laboratories
    $ABT
    10/10/2025$145.00Buy
    The Benchmark Company
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    Abbott Laboratories
    $ABT
    7/18/2025$145.00Hold → Buy
    Jefferies
    Abbott Laboratories
    $ABT
    6/16/2025$143.00Market Perform
    Leerink Partners
    Cytek Biosciences Inc.
    $CTKB
    5/9/2025$4.00Buy → Hold
    TD Cowen
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    More analyst ratings

    $ABT
    $CSII
    $CTKB
    $SPGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior Vice President Shroff Eric was granted 10,873 units of Common shares without par value, increasing direct ownership by 36% to 41,257 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/26/26 7:24:53 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EXECUTIVE VICE PRESIDENT Scoggins Christopher J was granted 18,502 units of Common shares without par value, increasing direct ownership by 29% to 82,123 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/26/26 7:15:24 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP AND GROUP PRESIDENT Salvadori Daniel Gesua Sive was granted 21,644 units of Common shares without par value, increasing direct ownership by 16% to 153,877 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/26/26 7:02:35 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    S&P Global to Present at the BofA Securities Information and Business Services Conference 2026 on March 12, 2026

    Session will be WebcastNEW YORK, Feb. 27, 2026 /PRNewswire/ -- Mark Grant, Senior Vice President of Investor Relations and Treasurer of S&P Global (NYSE:SPGI), will participate in the BofA Securities Information and Business Services Conference 2026 on March 12, 2026, in New York, NY. Mr. Grant is scheduled to speak from 9:20 a.m. to 9:55 a.m. (Eastern Daylight Time). The "fireside chat" will be webcast and may include forward-looking information. Heather Balsky, Senior Director of Investor Relations, will join for investor meetings. Webcast Instructions: Live and ReplayThe webcast (audio-only) will be available live and in replay through the Company's Investor Relations website http://inves

    2/27/26 4:00:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

    FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 2025 was $201.5 million, a 1% increase compared to the full year 2024Total recurring revenue, comprised of service and reagent revenues, grew 21% in 2025 compared to 2024, reaching 34% of

    2/26/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    US Secretary of Energy Chris Wright to Address CERAWeek by S&P Global in Houston, March 23-27

    World's preeminent energy conference to focus on 'Convergence and Competition: Energy,Technology and Geopolitics.' Learn more at www.ceraweek.comHOUSTON, Feb. 26, 2026 /PRNewswire/ -- U.S. Secretary of Energy Chris Wright will deliver a plenary address to delegates at the 44th annual CERAWeek by S&P Global, March 23-27 in Houston. Secretary Wright will join the world's energy industry leaders, experts, government officials and policymakers, as well as leaders from the technology, financial and industrial communities addressing this year's conference."We are pleased to welcome on

    2/26/26 12:00:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ABT
    $CSII
    $CTKB
    $SPGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on S&P Global with a new price target

    BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $575.00

    2/17/26 7:30:15 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Morgan Stanley resumed coverage on Cytek Biosciences with a new price target

    Morgan Stanley resumed coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $6.00

    12/2/25 8:24:49 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    SEC Filings

    View All

    SEC Form S-8 filed by Cytek Biosciences Inc.

    S-8 - Cytek Biosciences, Inc. (0001831915) (Filer)

    2/27/26 4:30:36 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-K filed by Cytek Biosciences Inc.

    10-K - Cytek Biosciences, Inc. (0001831915) (Filer)

    2/26/26 4:37:46 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

    2/26/26 4:17:25 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ABT
    $CSII
    $CTKB
    $SPGI
    Leadership Updates

    Live Leadership Updates

    View All

    S&P Global Appoints Chief Strategy Officer for Mobility Global Completing New Executive Leadership Team

    Martin Metzker to lead Strategy, Communications and Enterprise Marketing for Mobility Global in preparation for its planned separation into a standalone public companyNEW YORK, Feb. 19, 2026 /PRNewswire/ -- S&P Global (NYSE: SPGI) today announced the appointment of Martin Metzker as Chief Strategy Officer of S&P Global Mobility ("Mobility Global"), effective immediately. Mr. Metzker will be responsible for leading Mobility Global's Strategy function and overseeing Communications and Enterprise marketing for the business as it prepares for its planned separation from S&P Global into a standalone public company. Mr. Metzker joins the company from Boston Consulting Group, and will report to Bil

    2/19/26 4:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    RingCentral Set to Join S&P SmallCap 600

    NEW YORK, Feb. 9, 2026 /PRNewswire/ -- RingCentral Inc. (NYSE:RNG) will replace Hillenbrand Inc. (NYSE:HI) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, February 12. Lone Star Funds is acquiring Hillenbrand in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Feb 12, 2026 S&P SmallCap 600 Addition RingCentral RNG Information Technology Feb 12, 2026 S&P SmallCap 600 Deletion Hillenbrand HI Industrials ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices is the large

    2/9/26 6:08:00 PM ET
    $HI
    $RNG
    $SPGI
    Miscellaneous manufacturing industries
    Consumer Discretionary
    EDP Services
    Technology

    Merchants Bancorp Set to Join S&P SmallCap 600

    NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Merchants Bancorp (NASD: MBIN) will replace TreeHouse Foods Inc. (NYSE:THS) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 11. Investindustrial S.A. and its affiliates are acquiring Treehouse Foods in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Feb 11, 2026 S&P SmallCap 600 Addition Merchants Bancorp MBIN Financial Feb 11, 2026 S&P SmallCap 600 Deletion TreeHouse Foods THS Consumer Staples ABOUT S&P DOW

    2/6/26 6:24:00 PM ET
    $MBIN
    $SPGI
    $THS
    Major Banks
    Finance
    Finance: Consumer Services
    Packaged Foods

    $ABT
    $CSII
    $CTKB
    $SPGI
    Financials

    Live finance-specific insights

    View All

    Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

    FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 2025 was $201.5 million, a 1% increase compared to the full year 2024Total recurring revenue, comprised of service and reagent revenues, grew 21% in 2025 compared to 2024, reaching 34% of

    2/26/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Abbott declares 409th consecutive quarterly dividend

    ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 409th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio o

    2/20/26 11:38:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the n

    2/12/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ABT
    $CSII
    $CTKB
    $SPGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 4:35:51 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

    SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 1:42:15 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    2/22/24 7:07:27 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ABT
    $CSII
    $CTKB
    $SPGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Joly Hubert bought $997,459 worth of shares (2,500 units at $398.98), increasing direct ownership by 1,515% to 2,665 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    2/12/26 4:01:28 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care